Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
Switzerland (English)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      BV510 Mouse Anti-Human TRAIL-R1 (CD261)
      Product Details
      Down Arrow Up Arrow


      BD OptiBuild™
      TNFRSF10A; TRAIL Receptor 1; TRAIL-R1; APO2; DR4; Death receptor 4
      Human (Tested in Development)
      Mouse IgG1, κ
      Human TRAIL-R1 Recombinant Protein
      Flow cytometry (Qualified)
      0.2 mg/ml
      AB_2742590
      Aqueous buffered solution containing ≤0.09% sodium azide.
      RUO


      Preparation And Storage

      Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV510 under optimal conditions that minimize unconjugated dye and antibody.
      Show More blue down arrow Show Less blue up arrow

      Recommended Assay Procedures

      For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

      Show More blue down arrow Show Less blue up arrow

      Product Notices

      1. This antibody was developed for use in flow cytometry.
      2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
      3. Researchers should determine the optimal concentration of this reagent for their individual applications.
      4. An isotype control should be used at the same concentration as the antibody of interest.
      5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
      6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
      7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
      9. BD Horizon Brilliant Violet 510 is covered by one or more of the following US patents: 8,575,303; 8,354,239.
      Show More blue down arrow Show Less blue up arrow
      744933 Rev. 1
      Antibody Details
      Down Arrow Up Arrow
      S35-934

      The S35-934 monoclonal antibody specifically binds to TNF-related apoptosis inducing ligand receptor 1 (TRAIL-R1/TRAIL Receptor 1). TRAIL-R1 is also known as CD261, Death Receptor 4 (DR4) and APO2. TRAIL-R1 is a type I transmembrane protein that is encoded by TNFRSF10A (tumor necrosis factor receptor superfamily, member 10a). It serves as a receptor for TNF-related apoptosis-inducing ligand (TRAIL) which is also known as CD253 and TNFSF10.  TRAIL-R1 is expressed by a variety of tumor-derived cell lines. It is generally expressed at very low levels by most leucocytes. When bound by TRAIL, TRAIL-R1 can promote recruitment and subsequent activation of caspase-8, ultimately triggering the activation of effector caspases within cells that lead to apoptosis. Many transformed cell types are susceptible to TRAIL:TRAIL-R1-mediated cell death whereas normal cells are typically resistant.

      The antibody was conjugated to BD Horizon™ BV510 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 405-nm and Em Max at 510-nm, BD Horizon BV510 can be excited by the violet laser and detected in the BD Horizon V500 (525/50-nm) filter set. BD Horizon BV510 conjugates are useful for the detection of dim markers off the violet laser.

      744933 Rev. 1
      Format Details
      Down Arrow Up Arrow
      BV510
      The BD Horizon Brilliant Violet™ 510 (BV510) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye with an excitation maximum (Ex Max) at 327-nm / 405-nm and an emission maximum (Em Max) at 512-nm. BV510, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 510-nm (e.g., a 525/50 bandpass filter). The dye can be excited by the UV (355-nm) laser resulting in cross-laser excitation and spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
      altImg
      BV510
      Violet 405 nm
      327 nm, 405 nm
      512 nm
      744933 Rev.1
      Citations & References
      Down Arrow Up Arrow

      Development References (8)

      1. Dickens LS, Boyd RS, Jukes-Jones R, et al. A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol Cell. 2012; 47(2):291-305. (Biology). View Reference
      2. Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. Immunology. 2009; 127(2):145-154. (Biology). View Reference
      3. Florian S, Sonneck K, Czerny M, et al. Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies. Allergy. 2006; 61(9):1054-1062. (Biology). View Reference
      4. Grewal IS. Overview of TNF superfamily: a chest full of potential therapeutic targets. Adv Exp Med Biol. 2009; 647:1-7. (Biology). View Reference
      5. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset,progression and therapy. Nat Rev Cancer. 2008; 8(10):782-798. (Biology). View Reference
      6. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science. 1997; 276(5309):111-113. (Biology). View Reference
      7. Spierings DC, de Vries EG, Vellenga E, et al. Tissue distribution of the death ligand 2 TRAIL and its receptors. J Histochem Cytochem. 2004; 52(6):821-831. (Biology). View Reference
      8. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995; 3(6):673-682. (Biology). View Reference
      View All (8) View Less
      744933 Rev. 1

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.

      Website Feedback